STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas
Recruiting now · Phase 1/Phase 2
Conditions studied: Solid Tumor, Sarcoma, Leiomyosarcoma, Dedifferentiated Liposarcoma
In brief
This early phase oncology trial will be conducted at various study centers to investigate the safety, tolerability, and antitumor activity of STC-15 (a METTL3 inhibitor) in combination with toripalimab (anti- programmed cell death 1 \[PD-1\]) in advanced unresectable or metastatic tumors. The Phase 2 Monotherapy part is an open-label, non-randomized, multicenter Simon's 2-stage design that investigates the safety, tolerability, and antitumor activity of STC-15 in participants with selected, relapsed sarcomas subtypes, dedifferentiated (DD) liposarcoma and leiomyosarcoma (uterine and non-uterine).
Key facts
- Study ID
- NCT06975293
- Run by
- STORM Therapeutics LTD
- People needed
- 107
- Starts
- 2025-05-05
- Expected to finish
- 2028-06-29
- Last updated by the study team
- 2026-07-20
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- NEXT Oncology — Fairfax, Virginia, United States (enrolling)
- Dana Farber Cancer Institute — Boston, Massachusetts, United States (enrolling)
- Northwell Health Cancer Institute — Lake Success, New York, United States (enrolling)
- University of California, San Francisco — San Francisco, California, United States (enrolling)
- NEXT Houston — Houston, Texas, United States (enrolling)
- NEXT Dallas — Irving, Texas, United States (enrolling)
- NEXT Oncology — San Antonio, Texas, United States (enrolling)
- The START Center — San Antonio, Texas, United States (enrolling)
- MD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.